Yahoo Finance

Biosight Encourages Advaxis Stockholders to Vote “FOR” Proposed Merger

I am reaching out to you to share our excitement over Biosight’s proposed merger with Advaxis, Inc. (Nasdaq: ADXS) and explain why we believe the transaction represents a mutually compelling ...
Yahoo Finance

Advaxis and Biosight Announce Entry into Definitive Merger Agreement

MONMOUTH JUNCTION, N.J. and AIRPORT CITY, Israel, July 06, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (“Advaxis”) (NASDAQ: ADXS) and Biosight Ltd. (“Biosight”), a privately held pharmaceutical development ...
Medindia

Biosight Granted Orphan Drug Designation from the FDA for Aspacytarabine for the Treatment of Myelodysplastic Syndromes

"We are very pleased to have received from the FDA the Orphan Drug Designation for aspacytarabine for the treatment of MDS, which adds to the designation granted already for the treatment of AML" said ...
Business Insider

Biosight Receives Orphan Drug Designation From the FDA for BST-236 for the Treatment of Acute Myeloid Leukemia

AIRPORT CITY, Israel, June 4, 2019 /PRNewswire/ -- Biosight Ltd., a pharmaceutical development company focused on the development of novel oncology therapeutics, announced today that the United States ...
WFLA News Channel 8

Biosight Launches a Phase 1/2 Clinical Trial of Aspacytarabine in Combination with Venetoclax for First-Line AML Induction Therapy, Followed by Aspacytarabine Consolidation

AIRPORT CITY, Israel, Nov. 22, 2022 /PRNewswire/ -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced ...
Medindia

BioSight Launches a Phase 2b Clinical Trial of BST-236 as a First-Line Treatment of Acute Myeloid Leukemia

AIRPORT CITY, Israel, July 11, 2018 /PRNewswire/ -- BioSight Ltd., a pharmaceutical development company focused on the development of targeted oncology drugs, announced today that it has received the ...
The Times of Israel

Leukemia cure could be on the way, says med-tech firm Biosight

Biosight, an Israeli pharmaceutical development company that is working on a cure for leukemia, this week closed an investment of $13 million led by pharmaceutical investment firm Arkin Holdings, run ...
Finanznachrichten

Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement

Biosight is a private clinical stage biotech company developing innovative therapeutics for hematological malignancies and disorders. Biosight's lead product, aspacytarabine (BST-236), is an ...
Business Insider

Biosight to Present at the Jefferies 2020 Virtual Healthcare Conference

AIRPORT CITY, Israel, May 26, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today ...
Mena FN

Biosight Appoints Dr. Darrel Cohen as Chief Medical

AIRPORT CITY, Israel, May 18, 2021 (GLOBE NEWSWIRE) -- ., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced the ...
Mena FN

Bionext Launches Biosight: an Online Platform That Will Revolutionize Pharmaceutical Research

(BUSINESS WIRE)-- Bionext, a bioinformatics company, announces today the launch of BioSight, an online bio-simulation platform designed for efficient identification of possible side effects of ...